<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02903823</url>
  </required_header>
  <id_info>
    <org_study_id>151399</org_study_id>
    <nct_id>NCT02903823</nct_id>
  </id_info>
  <brief_title>Intrathecal (IT) Baclofen Drug Distribution</brief_title>
  <acronym>ITB</acronym>
  <official_title>Intrathecal (IT) Baclofen Drug Distribution Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this pilot study to determine whether there is a significant therapeutic&#xD;
      advantage to place the ITB catheter within the cervical, thoracic or lumbar region of the&#xD;
      spine. It is also a goal of this pilot study to determine whether the origin of spasticity&#xD;
      influences the effect of Lioresal Intrathecal (baclofen injection) on ITB catheters located&#xD;
      in the cervical, thoracic or lumbar regions of the spine. The investigators propose to study&#xD;
      the impact of catheter location on the reduction in spasticity within a group of patients who&#xD;
      are scheduled for ITB trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While ITB therapy is commonly recommended for treatment of severe spasticity due to a variety&#xD;
      of diseases, the location of optimal drug (baclofen) delivery has not been defined in a&#xD;
      controlled study. Furthermore, the cost of pharmacological management in these patients is&#xD;
      significant, and optimal location for drug delivery through an implantable drug pump may have&#xD;
      significant impact on the cost burden of maintenance refills. It is the goal of this pilot&#xD;
      study to determine whether there is a significant therapeutic advantage to place the ITB&#xD;
      catheter within the cervical, thoracic or lumbar region of the spine. It is also a goal of&#xD;
      this pilot study to determine whether the origin of spasticity influences the effect of&#xD;
      Lioresal Intrathecal (baclofen injection) on ITB catheters located in the cervical, thoracic&#xD;
      or lumbar regions of the spine. The investigators propose to study the impact of catheter&#xD;
      location on the reduction in spasticity within a group of patients who are scheduled for ITB&#xD;
      trial. In studying the impact of catheter location among patients with spinal versus cerebral&#xD;
      origin of spasticity, the disease origin may also have a significant impact on baclofen&#xD;
      dosing relative to the placement of the catheter.&#xD;
&#xD;
      In addition, the pharmacokinetic half-life and the variability of intrathecal baclofen is&#xD;
      poorly understood as data is limited. In order to provide initial data regarding CSF baclofen&#xD;
      washout, samples of spinal fluid obtained just prior to- and following IT baclofen&#xD;
      administration will be obtained for delayed analysis. The results of these pharmacological&#xD;
      analysis may refine the understanding of how quickly baclofen is distributed from a given&#xD;
      catheter location, and whether it is affected by catheter location or disease origin. Since&#xD;
      multiple catheter locations will be studied within a given patient, it also affords the&#xD;
      opportunity to sample small amounts of CSF at key anatomical sites along the spinal axis as a&#xD;
      secondary objective.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 22, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">February 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjects Experiencing Maximal MAS Change From Baseline - Spasticity of Cerebral Origin</measure>
    <time_frame>Baseline to 6 hours post-injection</time_frame>
    <description>The Modified Ashworth Scale (MAS) is a 6-point scale (Standard MAS scale values: &quot;0, 1, 1.5, 2, 3, or 4&quot;) used to evaluate spasticity based on grading muscle tone by moving joints. The MAS scores in this cohort are measured in biceps, triceps and forearm flexor muscles in upper extremities; and quadriceps, hamstrings and gastrocnemius muscles in lower extremities. The score ranges from 0 (no increase in muscle tone) to 4 (affected part(s) rigid in flexion or extension). Improvement in spasticity was a reduction in MAS score by 1 point across a joint tested. Maximal MAS change is the sum of MAS score reduction in all four limbs tested.&#xD;
This outcome looks at subjects with spasticity of cerebral origin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjects Experiencing Maximal MAS Change From Baseline - Spasticity of Spinal Origin</measure>
    <time_frame>Baseline to 6 hours post-injection</time_frame>
    <description>The Modified Ashworth Scale (MAS) is a 6-point scale (Standard MAS scale values: &quot;0, 1, 1.5, 2, 3, or 4&quot;) used to evaluate spasticity based on grading muscle tone by moving joints. The MAS scores in this cohort are measured in biceps, triceps and forearm flexor muscles in upper extremities; and quadriceps, hamstrings and gastrocnemius muscles in lower extremities. The score ranges from 0 (no increase in muscle tone) to 4 (affected part(s) rigid in flexion or extension). Improvement in spasticity was a reduction in MAS score by 1 point across a joint tested. Maximal MAS change is the sum of MAS score reduction in all four limbs tested.&#xD;
This outcome looks at subjects with spasticity of spinal origin.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Muscle Spasticity</condition>
  <arm_group>
    <arm_group_label>Baclofen injection at designated spinal level</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Days 2,3,4,5 a baclofen injection bolus will be given in the catheter, located at C4, T4, T10 and L2 respectively. Effect of baclofen injection (50 microgram bolus) upon rigidity will be assessed manually using the Modified Ashworth rating score for selected upper and lower extremities.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baclofen bolus injection</intervention_name>
    <description>A baclofen bolus injection (50 micrograms) will be administered daily after the patient returns from radiology to position catheter injection location. The injection may be given at C4, T4, T10 or L2 spinal locations depending on the catheter tip location.</description>
    <arm_group_label>Baclofen injection at designated spinal level</arm_group_label>
    <other_name>Injection of baclofen bolus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult patients with spasticity from spinal origin (spinal cord injury)&#xD;
&#xD;
          2. Adult patients with spasticity of cerebral origin (cerebral palsy and cerebrovascular&#xD;
             accident)&#xD;
&#xD;
          3. Adult women of child bearing age with a negative pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with spasticity from Multiple sclerosis&#xD;
&#xD;
          2. Pregnant women&#xD;
&#xD;
          3. Patients under the age of 18 years&#xD;
&#xD;
          4. Patients over the age of 50&#xD;
&#xD;
          5. Patients who are unable to have an MRI scan of the total spine&#xD;
&#xD;
          6. Patients with spinal deformity that would prevent easy access to the lumbar&#xD;
             intrathecal space&#xD;
&#xD;
          7. Patients who have an allergic reaction to IT baclofen&#xD;
&#xD;
          8. Patients who have significant headache from CSF withdrawal&#xD;
&#xD;
          9. Patients who have intradural blockage that prevents advancing the IT catheter to the&#xD;
             level of C4&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://nans.planion.com/Web.User/PDFViewer?ACCOUNT=NANS&amp;conf=AM18&amp;ssoOverride=OFF&amp;ckey=&amp;PDFID=1bea1414-bae6-4c4c-a371-b9568c65255c&amp;AUDIOID=&amp;VIDEOID=</url>
    <description>NANS 2018 ePoster</description>
  </link>
  <reference>
    <citation>Penn RD. Catheter implant systems for intrathecal drug delivery. J Neurosurg. 1996 Apr;84(4):713.</citation>
    <PMID>8613874</PMID>
  </reference>
  <reference>
    <citation>Kroin JS, Ali A, York M, Penn RD. The distribution of medication along the spinal canal after chronic intrathecal administration. Neurosurgery. 1993 Aug;33(2):226-30; discussion 230.</citation>
    <PMID>7690122</PMID>
  </reference>
  <reference>
    <citation>Grabb PA, Guin-Renfroe S, Meythaler JM. Midthoracic catheter tip placement for intrathecal baclofen administration in children with quadriparetic spasticity. Neurosurgery. 1999 Oct;45(4):833-6; discussion 836-7.</citation>
    <PMID>10515478</PMID>
  </reference>
  <reference>
    <citation>Albright AL. Technique for insertion of intraventricular baclofen catheters. J Neurosurg Pediatr. 2011 Oct;8(4):394-5. doi: 10.3171/2011.7.PEDS11211.</citation>
    <PMID>21961547</PMID>
  </reference>
  <reference>
    <citation>Coffey JR, Cahill D, Steers W, Park TS, Ordia J, Meythaler J, Herman R, Shetter AG, Levy R, Gill B, et al. Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J Neurosurg. 1993 Feb;78(2):226-32.</citation>
    <PMID>8421205</PMID>
  </reference>
  <reference>
    <citation>Albright AL, Turner M, Pattisapu JV. Best-practice surgical techniques for intrathecal baclofen therapy. J Neurosurg. 2006 Apr;104(4 Suppl):233-9.</citation>
    <PMID>16619633</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 26, 2016</study_first_submitted>
  <study_first_submitted_qc>September 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2016</study_first_posted>
  <results_first_submitted>April 21, 2020</results_first_submitted>
  <results_first_submitted_qc>April 1, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 27, 2021</results_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Peter Konrad</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>spinal cord injury</keyword>
  <keyword>cerebral palsy</keyword>
  <keyword>stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Spasticity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Baclofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 5, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT02903823/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All subjects recruited through Vanderbilt University Adult Neurosurgery group in Nashville, TN.&#xD;
Intent was to enroll subjects until 20 completed the study. Hence 7 more subjects were enrolled than completed. That makes 27 that started the study and 20 completed it.&#xD;
.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Baclofen Injection at Designated Spinal Level</title>
          <description>Days 2,3,4,5 a baclofen injection bolus will be given in the catheter, located at C4, T4, T10 and L2 respectively. Effect of baclofen injection (50 microgram bolus) upon rigidity will be assessed manually using the Modified Ashworth rating score for selected upper and lower extremities.&#xD;
Baclofen bolus injection: A baclofen bolus injection (50 micrograms) will be administered daily after the patient returns from radiology to position catheter injection location. The injection may be given at C4, T4, T10 or L2 spinal locations depending on the catheter tip location.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27">First subject enrollment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Could not advance catheter</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Catheter dislodgement</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects who were assessed after initial catheter placement with baseline MAS and spasm scores.</population>
      <group_list>
        <group group_id="B1">
          <title>Baclofen Injection at Designated Spinal Level</title>
          <description>Days 2,3,4,5 a baclofen injection bolus will be given in the catheter, located at C4, T4, T10 and L2 respectively. Effect of baclofen injection (50 microgram bolus) upon rigidity will be assessed manually using the Modified Ashworth rating score for selected upper and lower extremities.&#xD;
Baclofen bolus injection: A baclofen bolus injection (50 micrograms) will be administered daily after the patient returns from radiology to position catheter injection location. The injection may be given at C4, T4, T10 or L2 spinal locations depending on the catheter tip location.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" lower_limit="20" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjects Experiencing Maximal MAS Change From Baseline - Spasticity of Cerebral Origin</title>
        <description>The Modified Ashworth Scale (MAS) is a 6-point scale (Standard MAS scale values: &quot;0, 1, 1.5, 2, 3, or 4&quot;) used to evaluate spasticity based on grading muscle tone by moving joints. The MAS scores in this cohort are measured in biceps, triceps and forearm flexor muscles in upper extremities; and quadriceps, hamstrings and gastrocnemius muscles in lower extremities. The score ranges from 0 (no increase in muscle tone) to 4 (affected part(s) rigid in flexion or extension). Improvement in spasticity was a reduction in MAS score by 1 point across a joint tested. Maximal MAS change is the sum of MAS score reduction in all four limbs tested.&#xD;
This outcome looks at subjects with spasticity of cerebral origin.</description>
        <time_frame>Baseline to 6 hours post-injection</time_frame>
        <population>Subjects with pre-surgical diagnosis of spasticity of cerebral origin.</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects With Max MAS Change</title>
            <description>Days 2,3,4,5 a baclofen injection bolus will be given in the catheter, located at C4, T3, T10 and L2 respectively. Effect of baclofen injection (50 microgram bolus) upon rigidity will be assessed manually using the Modified Ashworth rating score for selected upper and lower extremities.&#xD;
Baclofen bolus injection: A baclofen bolus injection (50 micrograms) will be administered daily after the patient returns from radiology to position catheter injection location. The injection may be given at C4, T4, T10 or L2 spinal locations depending on the catheter tip location.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Experiencing Maximal MAS Change From Baseline - Spasticity of Cerebral Origin</title>
          <description>The Modified Ashworth Scale (MAS) is a 6-point scale (Standard MAS scale values: &quot;0, 1, 1.5, 2, 3, or 4&quot;) used to evaluate spasticity based on grading muscle tone by moving joints. The MAS scores in this cohort are measured in biceps, triceps and forearm flexor muscles in upper extremities; and quadriceps, hamstrings and gastrocnemius muscles in lower extremities. The score ranges from 0 (no increase in muscle tone) to 4 (affected part(s) rigid in flexion or extension). Improvement in spasticity was a reduction in MAS score by 1 point across a joint tested. Maximal MAS change is the sum of MAS score reduction in all four limbs tested.&#xD;
This outcome looks at subjects with spasticity of cerebral origin.</description>
          <population>Subjects with pre-surgical diagnosis of spasticity of cerebral origin.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cervical level 4 injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thoracic level 3 injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thoracic level 10 injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lumbar lever 2 injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subjects Experiencing Maximal MAS Change From Baseline - Spasticity of Spinal Origin</title>
        <description>The Modified Ashworth Scale (MAS) is a 6-point scale (Standard MAS scale values: &quot;0, 1, 1.5, 2, 3, or 4&quot;) used to evaluate spasticity based on grading muscle tone by moving joints. The MAS scores in this cohort are measured in biceps, triceps and forearm flexor muscles in upper extremities; and quadriceps, hamstrings and gastrocnemius muscles in lower extremities. The score ranges from 0 (no increase in muscle tone) to 4 (affected part(s) rigid in flexion or extension). Improvement in spasticity was a reduction in MAS score by 1 point across a joint tested. Maximal MAS change is the sum of MAS score reduction in all four limbs tested.&#xD;
This outcome looks at subjects with spasticity of spinal origin.</description>
        <time_frame>Baseline to 6 hours post-injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subjects With MAS Change - Based on Site of Injection</title>
            <description>Days 2,3,4,5 a baclofen injection bolus will be given in the catheter, located at C4, T3, T10 and L2 respectively. Effect of baclofen injection (50 microgram bolus) upon rigidity will be assessed manually using the Modified Ashworth rating score for selected upper and lower extremities.&#xD;
Baclofen bolus injection: A baclofen bolus injection (50 micrograms) will be administered daily after the patient returns from radiology to position catheter injection location. The injection may be given at C4, T4, T10 or L2 spinal locations depending on the catheter tip location.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Experiencing Maximal MAS Change From Baseline - Spasticity of Spinal Origin</title>
          <description>The Modified Ashworth Scale (MAS) is a 6-point scale (Standard MAS scale values: &quot;0, 1, 1.5, 2, 3, or 4&quot;) used to evaluate spasticity based on grading muscle tone by moving joints. The MAS scores in this cohort are measured in biceps, triceps and forearm flexor muscles in upper extremities; and quadriceps, hamstrings and gastrocnemius muscles in lower extremities. The score ranges from 0 (no increase in muscle tone) to 4 (affected part(s) rigid in flexion or extension). Improvement in spasticity was a reduction in MAS score by 1 point across a joint tested. Maximal MAS change is the sum of MAS score reduction in all four limbs tested.&#xD;
This outcome looks at subjects with spasticity of spinal origin.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cervical spine level 4 injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thoracic level 3 injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thoracic level 10 injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lumbar level 2 injection site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Baclofen Injection at Designated Spinal Level</title>
          <description>Days 2,3,4,5 a baclofen injection bolus will be given in the catheter, located at C4, T3, T10 and L2 respectively. Effect of baclofen injection (50 microgram bolus) upon rigidity will be assessed manually using the Modified Ashworth rating score for selected upper and lower extremities.&#xD;
Baclofen bolus injection: A baclofen bolus injection (50 micrograms) will be administered daily after the patient returns from radiology to position catheter injection location. The injection may be given at C4, T4, T10 or L2 spinal locations depending on the catheter tip location.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter dislodgement</sub_title>
                <description>catheter dislodged from location during manipulation in middle of study</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small number of subjects. Non-randomized trial. Inter-rater variability of assessments.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Peter Konrad, MD PhD - PI</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>6153439822</phone>
      <email>peter.konrad@vumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

